MX2022010912A - Combinacion de un inhibidor de desmetilasa-1 especifica de lisina (lsd-1) y nivolumab para usarse en el tratamiento de cancer de pulmon de celulas peque?as (sclc) o cancer de pulmon de celulas no peque?as escamosas (sqnsclc). - Google Patents

Combinacion de un inhibidor de desmetilasa-1 especifica de lisina (lsd-1) y nivolumab para usarse en el tratamiento de cancer de pulmon de celulas peque?as (sclc) o cancer de pulmon de celulas no peque?as escamosas (sqnsclc).

Info

Publication number
MX2022010912A
MX2022010912A MX2022010912A MX2022010912A MX2022010912A MX 2022010912 A MX2022010912 A MX 2022010912A MX 2022010912 A MX2022010912 A MX 2022010912A MX 2022010912 A MX2022010912 A MX 2022010912A MX 2022010912 A MX2022010912 A MX 2022010912A
Authority
MX
Mexico
Prior art keywords
sqnsclc
nivolumab
lsd
inhibitor
combination
Prior art date
Application number
MX2022010912A
Other languages
English (en)
Spanish (es)
Inventor
Brian Fox
Ellen Filvaroff
Eric Olson
Maria Wang
Ida Aronchik
Tracy Chow
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of MX2022010912A publication Critical patent/MX2022010912A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022010912A 2020-03-06 2021-03-05 Combinacion de un inhibidor de desmetilasa-1 especifica de lisina (lsd-1) y nivolumab para usarse en el tratamiento de cancer de pulmon de celulas peque?as (sclc) o cancer de pulmon de celulas no peque?as escamosas (sqnsclc). MX2022010912A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062986541P 2020-03-06 2020-03-06
PCT/US2021/021101 WO2021178807A1 (en) 2020-03-06 2021-03-05 Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc

Publications (1)

Publication Number Publication Date
MX2022010912A true MX2022010912A (es) 2022-11-09

Family

ID=77614361

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010912A MX2022010912A (es) 2020-03-06 2021-03-05 Combinacion de un inhibidor de desmetilasa-1 especifica de lisina (lsd-1) y nivolumab para usarse en el tratamiento de cancer de pulmon de celulas peque?as (sclc) o cancer de pulmon de celulas no peque?as escamosas (sqnsclc).

Country Status (11)

Country Link
US (1) US20230089536A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114398A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023516745A (cg-RX-API-DMAC7.html)
KR (1) KR20220151637A (cg-RX-API-DMAC7.html)
CN (1) CN115484958A (cg-RX-API-DMAC7.html)
AU (1) AU2021230575A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017637A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170456A1 (cg-RX-API-DMAC7.html)
IL (1) IL296564A (cg-RX-API-DMAC7.html)
MX (1) MX2022010912A (cg-RX-API-DMAC7.html)
WO (1) WO2021178807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
TW202329934A (zh) * 2021-09-30 2023-08-01 日商大鵬藥品工業股份有限公司 使用聯苯化合物及免疫檢查點分子調節劑之用於癌症的組合療法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
WO2015168466A1 (en) 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2019075327A1 (en) * 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. TREATMENT OF MERKEL CELL CARCINOMA
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
AU2018377852B2 (en) * 2017-11-29 2022-03-24 Epiaxis Therapeutics Pty Ltd Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist
CA3143030A1 (en) * 2019-06-13 2020-12-17 Celgene Corporation Methods of treating cancer by targeting cold tumors

Also Published As

Publication number Publication date
EP4114398A1 (en) 2023-01-11
CN115484958A (zh) 2022-12-16
JP2023516745A (ja) 2023-04-20
BR112022017637A2 (pt) 2022-11-08
US20230089536A1 (en) 2023-03-23
KR20220151637A (ko) 2022-11-15
CA3170456A1 (en) 2021-09-10
WO2021178807A1 (en) 2021-09-10
IL296564A (en) 2022-11-01
AU2021230575A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
EP4424375A3 (en) Antineoplastic combinations of neratinib and capecitabine
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
WO2019169065A3 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
EP4389225A3 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
WO2018102687A3 (en) Combination therapy for treating cancer
AU2018271862A1 (en) Combination therapy
WO2023081830A3 (en) Compositions and treatments with nirogacestat
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
PH12022550130A1 (en) Enzyme inhibitors
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
MX2025010157A (es) Metodo de preparacion y uso de un derivado de dihidrotienopirimidina
WO2019204332A3 (en) Pak4 inhibitors and methods of use
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
BR112022017637A2 (pt) Métodos de tratamento do câncer de pulmão de células pequenas e/ou câncer de pulmão de células não pequenas
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
EP4397752A3 (en) Methods for obtaining induced smooth muscle cells
EP4545072A3 (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression